Bionet

Bionet EBITDA per Employee

The EBITDA per Employee of Bionet (1784.TWO) as of Nov 2, 2026 is -102,584.75 TWD. In the previous year, EBITDA per Employee was 594,923.73 TWD — a change of -117.24% (lower).

EBITDA per Employee

-102,584.75TWD

YoY

-117.24%

Last updated:

EBITDA per Employee of Bionet is 2025 -102,584.75 TWD. EBITDA per Employee of Bionet was 2024 594,923.73 TWD. It decreases by -117.24% lower compared to the previous year.

The Bionet EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
298,872.88 TWD
Jan 1, 2019
86,542.37 TWD
Jan 1, 2020
97,694.92 TWD
Jan 1, 2021
420,000.00 TWD
Jan 1, 2022
700,864.41 TWD
Jan 1, 2023
986,618.64 TWD
Jan 1, 2024
594,923.73 TWD
Jan 1, 2025
-102,584.75 TWD
The Bionet EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-102,584.75TWD-117.24%
594,923.73TWD-39.70%
986,618.64TWD+40.77%
700,864.41TWD+66.87%
420,000.00TWD+329.91%
97,694.92TWD+12.89%
86,542.37TWD-71.04%
298,872.88TWD-3,014.63%
-10,254.24TWD-94.65%
-191,720.34TWD-16,857.78%
1,144.07TWD-103.06%
-37,381.36TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

EBITDA per Employee of Bionet is -102,584.75 TWD in 2025.

EBITDA per Employee of Bionet changed from 594,923.73 TWD to -102,584.75 TWD, representing a -117.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Bionet since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Bionet historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Bionet

All Key Metrics — Bionet